Many Americans have flocked to cheaper, compounded versions of GLP-1 weight loss drugs in lieu of brand-name treatments. That ...

Revance Therapeutics accepts Crown Laboratories' $3.65/share acquisition offer over rival bid from Teoxane, ending battle for ...

EyePoint's Duravyu meets primary endpoint in Phase 2 DME trial, showing potential to compete with Regeneron's Eylea and Roche ...

Alys Pharmaceuticals is on the hunt for a large financing to carry forward its pipeline — an amalgamation of six Medicxi ...

GSK said it is holding steady in the face of ongoing regulatory and potential political pressures on its vaccines franchise, ...

Novo Nordisk reports 26% sales growth in 2024, but projects lower 2025 growth of 16-24%. Full-year Wegovy sales up 86%, ...

Amgen's obesity drug AMG-513 on clinical hold; company reaffirms obesity market ambitions while advancing MariTide program ...

All nine late-stage kidney cancer patients in a Phase 1 trial of a personalized vaccine remained cancer-free after more than three years of receiving treatment, researchers wrote in a Nature paper ...

Bristol Myers Squibb cuts 67 jobs in Lawrence Township, NJ, while Kyowa Kirin lays off 52 employees at Princeton facility, per NJ WARN notices.